Provided by Tiger Trade Technology Pte. Ltd.

bioAffinity Technologies Equity Warrants Exp 23 June 2027 Warrant

0.7000
+0.308979.00%
Post-market: 0.70000.00000.00%17:40 EDT
Volume:38.97K
Turnover:21.63K
Market Cap:19.93M
PE:-0.03
High:0.7900
Open:0.3542
Low:0.3255
Close:0.3911
52wk High:0.8121
52wk Low:0.0101
Shares:28.47M
Float Shares:28.47M
Volume Ratio:1.14
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-20.7379
ROE:-1860.15%
ROA:-125.11%
PB:5.29
PE(LYR):- -

Loading ...

bioAffinity Technologies Advances Cypath® Lung for Surveillance of Lung Cancer Survivors

THOMSON REUTERS
·
Sep 01

NASDAQ Trade Halt Continues Halt News Pending at 03:28 Am

Reuters
·
Aug 22

bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026

THOMSON REUTERS
·
Aug 20

bioAffinity Technologies and Avmedical Announce Nationwide Federal Healthcare Distribution Agreement for Cypath® Lung

THOMSON REUTERS
·
Aug 18

bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under NASDAQ Rules

THOMSON REUTERS
·
Aug 14

bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under NASDAQ Rules

THOMSON REUTERS
·
Aug 13

Bioaffinity Technologies - Tests Expected to be Offered as Laboratory Developed Tests Under Clia

THOMSON REUTERS
·
Jul 22

Bioaffinity Technologies - Partners with Pictor to Develop Asthma and Copd Diagnostics

THOMSON REUTERS
·
Jul 22

bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells

THOMSON REUTERS
·
Jun 22

bioAffinity Technologies Announces Closing of $3.2 Million Offering

THOMSON REUTERS
·
Jun 19

bioAffinity Technologies Announces Pricing of $3.2 Million Offering

THOMSON REUTERS
·
Jun 17

bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using Cypath® Lung Technology

THOMSON REUTERS
·
May 27

bioAffinity Technologies Inc - Total Consolidated Revenue Decreases 27% to $1.4 Mln in Q1 2026

THOMSON REUTERS
·
May 08

bioAffinity Technologies Inc - Q1 2026 Net Loss $3.6 Mln or $0.81 per Share

THOMSON REUTERS
·
May 08

bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic Cypath® Lung

THOMSON REUTERS
·
Mar 13

bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive Cypath® Lung Cancer Diagnostic

THOMSON REUTERS
·
Mar 10